Obesity, Genes and Aging….Overlapping Magisterium?

Posted on 03/10/2015 in Blog Post, Editorial

Chief Medical Officer

By Michael Nova, M.D.
Chief Innovation Officer
Pathway Genomics

There has recently (2013-15) been a flurry of human clinical trial publications regarding gene-diet interactions, primarily concerning obesity and related phenotypes.

A new finding by the Genetic Investigation of Anthropometric Traits, or GIANT, consortium has identified 97 gene regions associated with obesity, tripling the number of such genes previously known.

Despite this strong influence of genes in obesity, the environment can play as strong a part. It is estimated that 40 to 70 percent of the variation in obesity is caused by genetics. The remaining 30 to 60 percent can be attributed to the environment you live in.

There is now clear evidence that variants of genes such as APOA2, FTO, PPARg, FOXO, KLOTHO, DRD4 and others directly interact with micronutrients (or insulin) to regulate differing metabolism effects, and subsequently can tip individuals over to an obesogenic phenotype depending on environmental factors such as type of food consumed or eating behaviors (DRD4). As an example, FOXO is a transcription factor that plays important roles in regulation of gluconeogenesis and glycogenolysis by insulin signaling, and is also central to the decision for negatively regulating adipogenesis (fat production) and its vital in stem cell maintenance. FOXO has been found to be particularly active in centenarians — people older than one hundred years, which is why many believe that FOXO plays a key role in aging.

Genetic variants in KLOTHO have been associated with human aging, and KLOTHO protein has been shown to be a circulating factor detectable in blood serum that declines with age. It is also coincidental, that many of the gene combinations implicated in obesity and increased BMI are also manifest in the metabolism pathways now linked to aging.

As another example, mTOR (mechanistic target of rapamycin) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis. The pathway regulates many major cellular processes and is implicated in an increasing number of pathological conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration.

Much new data linking obesity/diabetes genotypes and anti-aging pathways and possible therapeutics (Rapamycin, Metformin) have also been shown. In fact, Rapamycin, an inhibitor of mechanistic target of Rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in lower life forms, such as c-elegans, and also mammals (mice, rats).

With the sum of all medical/healthcare knowledge doubling every three years, we are living in exciting times. With the new ‘omics and healthcare IT/computational biology technologies, we now have the ability to tease out the linkages between very complex biological pathways. This will assuredly lead to better and more Personalized precision medicine treatments for chronic conditions (like obesity) and maybe also into generalized anti-aging therapeutics or even micronutrients.

REFERENCES

  1. Kleinert S, Horton R. Rethinking and reframing obesity. Lancet. 2015 Feb 18. pii: S0140-6736(15)60163-5. doi: 10.1016/S0140-6736(15)60163-5. [Epub ahead of print] PubMed PMID: 25703115.
  2. Arking DE, Krebsova A, Macek M, et al. Association of human aging with a functional variant of klotho. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(2):856-861. doi:10.1073/pnas.022484299.
  3. Locke AE, Kahali B et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015 Feb 12;518(7538):197-206. doi: 10.1038/nature14177. PubMed PMID: 25673413.
  4. Ribarič S. Diet and aging. Oxid Med Cell Longev. 2012;2012:741468. doi: 10.1155/2012/741468. Epub 2012 Aug 13. Review. PubMed PMID: 22928085; PubMed Central PMCID: PMC3425961.
  5. Grady DL, Thanos PK et al. DRD4 genotype predicts longevity in mouse and human. J Neurosci. 2013 Jan 2;33(1):286-91. doi: 10.1523/JNEUROSCI.3515-12.2013. PubMed PMID: 23283341; PubMed Central PMCID: PMC3710129.
  6. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 2013 Mar;123(3):980-9. doi: 10.1172/JCI64099. Epub 2013 Mar 1. Review. PubMed PMID: 23454761; PubMed Central PMCID: PMC3582126.
  7. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017. Review. PubMed PMID: 22500797; PubMed Central PMCID: PMC3331679.
  8. Shadia Ragab, Nagwa Abdallah et al. FOXO 1a and FOXO 3a gene polymorphisms in association with metabolic syndrome, Journal of Genetic Engineering and Biotechnology, Volume 12, Issue 2, December 2014

Comments are closed.